The efficacy and safety of His purkinje system pacing and cardiac resynchronization therapy in patients with PICM: a randomized controlled study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034265

Enrollment

Unknown

Registered

2020-06-30

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pacing induced cardiomyopathy

Interventions

Group 1:HPSP

Group 2:CRT

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who meet all of the following 1-4 points and any of the5-6 points: 1. Patients who have been implanted with single-chamber/dual-chamber pacemakers/ICD; 2. Adults aged 18 to 80 years; 3. The duration of medication treatment is longer than 3 months; 4. Expected survival time>1 year; 5. Ventricular pacing proportion>40%,LVEF= 50%, LVEF =10% compared with before treatment.

Exclusion criteria

Exclusion criteria: 1. Unable to cooperate with follow-up; 2. eGFR < 30ml/min; 3. Septic shock; 4. Advanced malignant tumor; 5. Pregnancy or prepared to get pregnancy; 6. Cardiac tamponade or major hydropericardium; 7. Atrial fibrillation.

Design outcomes

Primary

Measure	Time frame
Duration of QRS complex;	—

Secondary

Measure	Time frame
LVEF;NT-proBNP;	—

Countries

China

Contacts

Public ContactYongquan Wu

Beijing Anzhen Hospital, Capital Medical University

wuyongquan67@126.com+86 13810751596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026